Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/135478
Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
In this retrospective
cohort study, we aimed to assess whether introducing
benznidazole at escalating doses reduces the probability of
adverse events or treatment discontinuation compared with a
full-dose scheme. We collected data from patients who had
chronic " - " infection and underwent treatment from July 2008
to January 2017 in a referral center in Madrid. Dose was
adjusted to body weight (5 mg/kg/day), with treatment
introduction with full dose or escalating dose according to
local consensus and protocols. Among the 62 patients treated,
benznidazole was introduced at full dose in 28 patients and on
escalating dose in the remaining 34. We found no statistical
differences in the number of adverse events, treatment
discontinuations, days of treatment, or sociodemographic
profiles. There is insufficient evidence to support escalating
dose as a strategy for reducing the adverse effects of
benznidazole. Further research is needed to evaluate this
strategy.
Subject
Subject (English)
Citation
Collections
Citation
LOSADA, Irene, et al. Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?. American Journal of Tropical Medicine and Hygiene. 2019. Vol. 100, num. 6, pags. 1477-1481. ISSN 0002-9637. [consulted: 17 of June of 2026]. Available at: https://hdl.handle.net/2445/135478